AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10979640
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy + long-acting nitrates, digoxin, aspirin, and furosemide
Trial: 8637340
Drug: Subcutaneous standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous standard heparin (5000 IU every 12 h) until hospital discharge or for a maximum of 3 weeks
Trial: 8637340
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic treatment (control group)
Trial: 30865526
Drug: semaglutide 0.5
RxNorm normalized name: semaglutide 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semaglutide 0.5 mg
Trial: 30865526
Drug: semaglutide 1.0
RxNorm normalized name: SEMAGLUTIDE 1.0 mg in 0.5 mL SUBCUTANEOUS INJECTION, SOLUTION [WEGOVY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semaglutide 1.0 mg
Trial: 30528641
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention (concurrent training: power training + high-intensity interval training, HIIT)
Trial: 26376112
Drug: Hi-PRO (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hi-PRO (1.5 g milk protein/100 mL)
Trial: 26376112
Drug: Lo-PRO (0.76
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lo-PRO (0.76 g milk protein/100 mL)
Trial: 26376112
Drug: CONT (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CONT (0 g milk protein/100 mL)
Trial: 25885382
Drug: Gabapentin 10
RxNorm normalized name: gabapentin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 10 mg/kg
Trial: 9075510
Drug: Paracetamol 20
RxNorm normalized name: Paracetamol 20 mg/mL oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 20 mg/kg
Trial: 16928714
Drug: Management pathway
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management pathway to improve early delivery of appropriate antibiotics, implemented using a multifaceted strategy.
Trial: 1689512
Drug: Oral rinse
RxNorm normalized name: Oral Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rinse consisting of hydrocortisone, nystatin, tetracycline, and diphenhydramine
Trial: 7368106
Drug: Metronidazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (2 gm the day before operation and 1.2 gm daily for 5 days after operation)
Trial: 7368106
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same dosage as metronidazole)
Trial: 24956042
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR (150-300 mg/day)
Trial: 9576164
Drug: Midazolam (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (2.0 mg for ≤50 kg, 2.5 mg for 50-80 kg, 3.0 mg for ≥80 kg)
Trial: 31969138
Drug: Medication Errors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Errors (ME) observed in patients
Trial: 31969138
Drug: Types of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Types of Medication Errors
Trial: 31969138
Drug: Drug associated
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug associated with ME
Trial: 30086277
Drug: Clomipramine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine 15 mg
Trial: 24968543
Drug: Low‐molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐molecular weight heparin (LMWH)
Trial: 16336486
Drug: BSW (patient-rated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSW (patient-rated global assessment of treatment benefit)
Trial: 16336486
Drug: Patients dissatisfied
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients dissatisfied with treatment
Trial: 16336486
Drug: Patients unwilling
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients unwilling to continue treatment
Trial: 12587378
Drug: Surgery and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery and concurrent chemoradiotherapy
Trial: 10099057
Drug: Iscador (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iscador (twice 0.1 mg and once 2.5 mg)
Trial: 10099057
Drug: Iscador (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iscador (2.5 mg)
Trial: 2679374
Drug: Pefloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin (400 mg i.v. or per os every 8 or 12 h for 7 to 180 days)
Trial: 2679374
Drug: Ceftazidime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (2 g i.v. every 8 h or 1 g intramuscularly every 8 h for 7 to 56 days)
Trial: 16009588
Drug: Budesonide/formoterol (320/9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (320/9 microg, two inhalations; total doses 1280/36 microg)
Trial: 16009588
Drug: Salbutamol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (100 microg x eight inhalations; total doses 1600 microg)
Trial: 2238665
Drug: Neomycin and
RxNorm normalized name: Neomycin and polymyxin B only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neomycin and erythromycin (1 g each) administered preoperatively to Group B patients.
Trial: 2238665
Drug: Cefoxitin or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin or cefotetan (2 g intravenously) administered preoperatively to Group C patients.
Trial: 2238665
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral and parenteral antibiotics in Group D patients.
Trial: 31727428
Drug: Tube shunt
RxNorm normalized name: Sus scrofa fallopian tube preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tube shunt (350-mm2 Baerveldt glaucoma implant)
Trial: 29477688
Drug: Trabeculectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy with mitomycin C (MMC; 0.4 mg/ml for 2 minutes)
Trial: 28785810
Drug: Splint +
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Splint + paraffin treatment (five consecutive days a week for 3 weeks)
Trial: 28785810
Drug: Splint treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Splint treatment (during the night and day time as much as possible for 3 weeks)
Trial: 23749244
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg zoledronic acid every 6 months over 3 years
Trial: 17943443
Drug: Postmenopausal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postmenopausal hormone therapy
Trial: 19952403
Drug: Aminophylline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (5 mg/kg) injected slowly via the vein after anesthesia and maintained at 0.5 mg/(kg.h) until the end of CPB
Trial: 19952403
Drug: Ringer's lactated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's lactated solution (control group)
Trial: 17264717
Drug: 8% sevoflurane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% sevoflurane in oxygen (8 l/min) via a prefilled circuit, end‐tidal sevoflurane maintained at 4%
Trial: 28911070
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (IC) with docetaxel/cisplatin/5 fluorouracil (TPF) followed by CCRT (Arm B1)
Trial: 28911070
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (IC) with docetaxel/cisplatin/5 fluorouracil (TPF) followed by CET/RT (Arm B2)
Trial: 28911070
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (IC) with docetaxel/cisplatin/5 fluorouracil (TPF) followed by CCRT or CET/RT
Trial: 28911070
Drug: Concomitant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant treatment alone with CCRT (Arm A1)
Trial: 28911070
Drug: Concomitant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant treatment alone with CET/RT (Arm A2)
Trial: 25580989
Drug: 0.38% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.38% ropivacaine continuous wound infusion (CWI) at 5 ml/h after laparotomy or 2 ml/h after laparoscopy
Trial: 25580989
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline continuous wound infusion (CWI) at 5 ml/h after laparotomy or 2 ml/h after laparoscopy
Trial: 21425884
Drug: Methylphenidate transdermal
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate transdermal system 10-30 mg
Trial: 12851662
Drug: Placebo transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo transdermal system
Trial: 21425884
Drug: Methylphenidate transdermal
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate transdermal system
Trial: 18417466
Drug: Antipsychotic cotreatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic cotreatment
Trial: 17055302
Drug: Thrombin-soaked gel
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombin-soaked gel foam
Trial: 17055302
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution lavage with sponge drying
Trial: 2010899
Drug: Three-day diet
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-day diet containing greater than 150 g/d of carbohydrate (group I)
Trial: 2010899
Drug: Normal dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal dietary pattern without dietary preparation (group II)
Trial: 3736281
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg diazepam
Trial: 6121766
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg buspirone hydrochloride
Trial: 6121766
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg buspirone hydrochloride
Trial: 27422154
Drug: 0.3mg rhTSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3mg rhTSH stimulation before radioiodine therapy (group I)
Trial: 25856740
Drug: Emotion-regulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emotion-regulation therapy combined with cognitive group therapy ('Before and beyond')
Trial: 25856740
Drug: Normal individual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal individual treatment
Trial: 21212432
Drug: Rituximab in
RxNorm normalized name: rituximab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab in combination with fludarabine and cyclophosphamide (FC)
Trial: 11675939
Drug: Diuretic (trichlormethiazide)
RxNorm normalized name: Trichlormethiazide
DrugBank: Trichlormethiazide (DB01021)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diuretic (trichlormethiazide)
Trial: 7701044
Drug: Cocaethylene (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaethylene (0.25 mg/kg cocaethylene base)
Trial: 7701044
Drug: Cocaine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (0.25 mg/kg cocaine base)
Trial: 22230406
Drug: Neo-adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-adjuvant chemotherapy with cisplatin and gemcitabine plus immunotherapy with PBMC and rIL-2
Trial: 22230406
Drug: Neo-adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-adjuvant chemotherapy with cisplatin and gemcitabine
Trial: 16924981
Drug: No-treatment (n=24)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment (n=24)
Trial: 15689090
Drug: Two-dose varicella
RxNorm normalized name: VARICELLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose varicella vaccine
Trial: 15689090
Drug: One-dose varicella
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-dose varicella vaccine
Trial: 14622777
Drug: 4030W92 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4030W92 (25 mg/day)
Trial: 7624492
Drug: Levetiracetam (pyrrolidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (pyrrolidine derivative) as an antiepileptic concomitant drug
Trial: 140824
Drug: Ro 11-1430
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 11-1430 (0.1% lotion)
Trial: 140824
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A acid (0.05% lotion)
Trial: 140824
Drug: Placebo (lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lotion alone)
Trial: 31495658
Drug: Multimodality stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodality stimulation combined with standard physiotherapy (therapy group)
Trial: 27794487
Drug: Direct skill
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct skill training (n=22, 10 sessions as adjunct to usual inpatient rehabilitation)
Trial: 27794487
Drug: Guided training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided training (n=21, same dose)
Trial: 12243915
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg/day for 5 years
Trial: 23335675
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg/day for 5 years
Trial: 17314736
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg/day + 17beta‐estradiol 1 mg/day (RLX + E)
Trial: 14752071
Drug: Oral fluoropyrimidines
RxNorm normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral fluoropyrimidines for 1 year
Trial: 11096006
Drug: Mupirocin treatment
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mupirocin treatment
Trial: 8956398
Drug: Subarachnoid neostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subarachnoid neostigmine 75 micrograms (1.5 mL)
Trial: 8956398
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received 1.5 mL subarachnoid saline
Trial: 8956398
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received 15 mg (3 mL) of hyperbaric bupivacaine 0.5%
Trial: 4055985
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg m‐CPP, orally
Trial: 28851788
Drug: Regional transarterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional transarterial hypothermic infusion (cold saline at 15°C) administered through a microcatheter in the ipsilateral internal carotid artery after thrombectomy when no improvement in NIHSS score is observed.
Trial: 23588685
Drug: Strawberry-flavored lozenge
RxNorm normalized name: pectin
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strawberry-flavored lozenge (Strepsils® strawberry sugar free)
Trial: 23588685
Drug: Orange-flavored lozenge
RxNorm normalized name: polyethylene glycol 3350
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange-flavored lozenge (Strepsils® orange with vitamin C)
Trial: 14687901
Drug: Benzbromarone treatment
RxNorm normalized name: benzbromarone
DrugBank: Benzbromarone (DB12319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzbromarone treatment
Trial: 11518893
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 150 mg fluconazole
Trial: 11518893
Drug: Two sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two sequential doses of 150 mg fluconazole given 3 days apart
Trial: 11518893
Drug: Two-dose fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two-dose fluconazole regimen
Trial: 11518893
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of fluconazole
Trial: 8853725
Drug: Fluconazole therapy
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole therapy
Trial: 3276469
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral and parenteral antimicrobial prophylaxis
Trial: 3276469
Drug: Parenteral antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral antimicrobial prophylaxis
Trial: 26412215
Drug: Mixed nuts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed nuts (30 g/d) for 12 weeks
Trial: 16540953
Drug: Oxygen catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen catheter (6 L/min)
Trial: 16540953
Drug: T-piece system
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-piece system (12 L/min)
Trial: 16540953
Drug: CPAP system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP system (10 cm H2O, 12 L/min)
Trial: 12880400
Drug: Carbon fibre
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbon fibre reinforced carbon (CFRC) endodontic post cemented with a composite luting agent
Trial: 11025363
Drug: THL 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THL 120 mg t.i.d.
Trial: 8881951
Drug: Finasteride treatment
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Finasteride treatment for a minimum of 9 months
Trial: 7646574
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg omeprazole daily
Trial: 1411281
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg famotidine daily
Trial: 30354562
Drug: DASH/SRD (Dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DASH/SRD (Dietary Approaches to Stop Hypertension meals; 1500 mg sodium/d)
Trial: 22678051
Drug: Caffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated coffee (237 ml, 182 mg caffeine)
Trial: 22678051
Drug: Decaffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated coffee (237 ml, 4 mg caffeine)
Trial: 20546197
Drug: Modified sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified sequential three-step empirical therapy
Trial: 20546197
Drug: Primary sequential
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary sequential three-step empirical therapy
Trial: 15697327
Drug: Mirtazapine 15-60
RxNorm normalized name: mirtazapine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine 15-60 mg/day (n = 147)
Trial: 15697327
Drug: Fluoxetine 20-40
RxNorm normalized name: fluoxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20-40 mg/day (n = 152)
Trial: 7805082
Drug: Warfarin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin and Aspirin combination
Trial: 7805082
Drug: Low-dose Warfarin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Warfarin
Trial: 2686257
Drug: ISDN/ISMN (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISDN/ISMN (120 mg/50 mg) + Diltiazem (D)
Trial: 2686257
Drug: ISDN/ISMN (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISDN/ISMN (120 mg/50 mg)
Trial: 2686257
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with Diltiazem (D)
Trial: 27844472
Drug: Tapentadol PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol PR (100-250 mg bid)
Trial: 24985410
Drug: Oxycodone CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone CR (20-50 mg bid)
Trial: 24831754
Drug: Individual drug
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual drug counseling in addition to buprenorphine-naloxone and medical management
Trial: 22540417
Drug: FertilMate™ Scrotum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FertilMate™ Scrotum Cooling Patch for 90 days
Trial: 22540417
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not wearing patches)
Trial: 11421509
Drug: Formoterol added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol added to low dose budesonide
Trial: 11421509
Drug: Formoterol added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol added to moderate doses of budesonide